ArticleFolia microbiologica2026
Computational identification and multi-level validation of marine fungal metabolites as potent inhibitors of Acinetobacter baumannii GuaB.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is a multidrug-resistant pathogen that causes serious nosocomial infections with limited therapeutic options. GuaB (Inosine Monophosphate Dehydrogenase, IMPDH) is an important target in purine biosynthesis that has been identified as a promising target in anti-A. baumannii drug research. The dCBS regulatory domain of GuaB has been purposefully chosen for this research due to its role in allosteric regulation and structural dissimilarity with its human homologue. The integrated computational framework has been utilized to identify new GuaB inhibitors among marine fungal metabolites. The virtual screening of GuaB-dCBS with AutoDock Vina identified three lead compounds: CMNPD27312, CMNPD12442, and CMNPD28769. Density functional theory calculations were carried out to refine the structures of the ligands before redocking with GuaB-dCBS to evaluate their electronic compatibility with GuaB. The calculations showed good electronic compatibility with GuaB-dCBS compared to the positive control compound A1AUF. Long timescale molecular dynamics simulations of 500 ns were carried out to evaluate the stability of the ligand-GuaB-dCBS complexes. The structural stability of all ligand-GuaB-dCBS complexes has been shown in this research. The RMSD, RMSF, and hydrogen bond analysis showed that CMNPD27312 and CMNPD28769 have enhanced stability. The binding free energy calculations showed good ligand binding to GuaB-dCBS. The principal component analysis showed ligand-induced stability of GuaB-dCBS. The free energy landscape calculations showed ligand-induced stability of GuaB-dCBS. The QM/MM calculations showed good electronic compatibility of the ligands with GuaB-dCBS. The bioactivity prediction showed that CMNPD27312 and CMNPD28769 have high inhibitory potential (predicted pIC50 ≥ 7.2).
Indexed as
Identifiers
41964791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.